Miraculins to Launch PreVuĀ® in United States through Texas Supermarket and Pharmacy Leader H-E-B

July 25, 2013

Miraculins Inc. (TSX-V:MOM), (”Miraculins” or “the Company”), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today the execution of an agreement with H-E-B, the #1 food retailer in South and Central Texas and the State’s largest private company, that will see the Phase One launch of its PreVu® Non-Invasive Skin Cholesterol Point of Care (POC) Test into the United States take place exclusively in 20 H-E-B Texas store locations to be determined, during the 4th quarter of 2013.

“The launch of PreVu into Texas and the United States is a very significant milestone for Miraculins, as well as a major step forward in the commercialization of the PreVu technology worldwide,” said Paul Moreau, Vice President, Sales and Marketing for Miraculins Inc. “We are very pleased that H-E-B, a leading supermarket/pharmacy chain with 340 stores in Texas and Northern Mexico and more than 76,000 employees, wants to make the PreVu POC Test available to its eligible customers to help them better understand and manage their risk of coronary artery disease (CAD). With over 1.5 million heart attacks occurring in the United States each year, resulting in over 500,000 deaths, this Phase One launch - leading to the potential of PreVu POC Testing Centres being located throughout H-E-B’s network of stores - represents an important step towards realizing greater heart health education, risk assessment and prevention for Texans and all Americans at risk.”

Pursuant to the agreement, on the completion of the Phase One launch H-E-B will have the option to expand PreVu POC testing to additional H-E-B locations commencing in 2014. Further details about the Phase One launch will be announced closer to the fourth quarter, and will include a full list of participating store locations as well as clinic dates and times.

About The PreVu® Non-Invasive Skin Cholesterol (POC) Test

The PreVu® Point of Care (POC) Test is a non-invasive, risk assessment technology designed to measure Skin Cholesterol – an important new biomarker in assessing risk of coronary artery disease (CAD). The PreVu® POC Test is completely painless, non-invasive, involves no blood draw or needles, and requires no overnight fasting.This in vitro diagnostic test is conducted on the palm of the hand in less than 5 minutes with results being immediately available, facilitating point of care consultation and a next steps discussion. Skin Cholesterol is the cholesterol that has been deposited and diffused into tissue, as opposed to freely circulating in the bloodstream, and the skin contains approximately 11% of all the cholesterol found in the human body. Elevated Skin Cholesterol has been shown in clinical studies to be strongly associated with significant CAD as measured by treadmill stress testing and coronary angiography, as well as measured by testing for coronary calcium, carotid artery thickening, and carotid artery plaque. The PreVu® Point of Care Test does not diagnose the presence or absence of CAD, but helps to identify patients who may be at higher, hidden risk for CAD by measuring this new biomarker. In the United States, Skin cholesterol as measured by the PreVu POC Test can be used as part of risk assessment for coronary heart disease in persons with a history of myocardial infarction and/or in persons suspected of having significant multi-vessel coronary artery disease (>50% stenosis in >1 vessel as diagnosed by coronary angiography) where further diagnostic evaluation is being considered. Test results, when considered in conjunction with clinical evaluation, blood cholesterol tests and other risk factors identified for coronary artery disease, will aid the physician in focusing diagnostic and patient management options. For more information visit www.prevu.com.

Share This Story